The reason for the agreement was that Novartis thought the Covid-ARDS trial would give them a good look as to whether or not MSB's treatment might have some efficacy in treating ARDS from any cause. After they had a year to scrutinise the trial data they didn't think it showed sufficient promise to be worth further investigation for Covid-related-ARDS or other causes of ARDS. Really what they were saying was it didn't appear to work.
Now Pfizer have approval for anti-antiviral pill which it seems decreases the chances of getting a serious Covid infection by 90%. So the chances of developing Covid-ARDS will be correspondingly reduced. And it seems that the market for the Pfizer pill is opening up rapidly world wide. The chances of success for MSB in this indication are surely remote. I suspect that that any further trials will sink slowly beneath the waves of time and we won't get any further mention of a new trial or partners after the coming cap raise which can't be far away now. I would pick before the end of February, since SI will want to get it away before he has to present the accounts and progress summary, so he can still talk up the potential pathways with potential partners in the meantime.
MSB Price at posting:
$1.09 Sentiment: Sell Disclosure: Not Held
(20min delay)